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Antibodies to citrullinated peptides are highly specific for rheumatoid arthritis (RA) and represent a significant risk factor for
undifferentiated polyarthritis. This prognostic ability may be related to the very diagnostic performance of these autoantibodies,
since RA is a more erosive disease than other forms of arthritis. The present study evaluated an association of antibodies to
citrullinated peptides and the rate of joint destruction in patients with a well-established diagnosis of RA. Seventy-one patients
with RA were evaluated in 1994 and again in 2002 (functional class, joint count, Health Assessment Questionnaire score, hands
X-ray). Autoantibodies (rheumatoid factor (RF), anti-perinuclear factor, anti-cyclic citrullinated peptide (CCP) antibodies) and
Sharp’s index were analyzed blindly. Delta Sharp was calculated as the difference in Sharp’s index obtained in 1994 and 2002.
During the follow-up the Health Assessment Questionnaire score increased from 0.91 ± 0.74 to 1.39 ± 0.72 (P < 0.001). Similarly,
the number of swollen joints increased from 4.6 ± 5.71 to 6.4 ± 4.1 (P = 0.002). The frequency of autoantibodies and anti-CCP
titer remained stable; however, serum RF concentration increased from 202.8 ± 357.6 to 416.6 ± 636.5 IU/mL (P = 0.003).
Sharp’s index increased from 56.7 ± 62.1 to 92.4 ± 80.9 (P < 0.001). No correlation was observed between Delta Sharp and the
presence of RF, anti-perinuclear factor, and anti-CCP antibodies at baseline. Antibodies to citrullinated epitopes are specific and
early markers for the diagnosis of RA but do not seem to be associated with the rate of joint destruction in patients with a well-
established diagnosis of RA.
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Introduction
The last decade has brought two important break-
throughs for the management and understanding of rheu-
matoid arthritis (RA). Heralded by monoclonal antibodies
to TNF-α, the class of biological therapeutic agents has
been shown to be able to favorably interfere with the
natural history of RA to an extent never achieved before,
especially when administered early in the course of the
disease (1). In the second half of the 1990’s, two systems
of autoantibodies previously known to be associated with
RA (anti-perinuclear factor (APF) and anti-keratin anti-
bodies) were shown to be part of the highly specific system
of antibodies to citrullinated epitopes (2,3). The last few
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years have provided plenty of evidence for the high diag-
nostic performance of the antibodies to citrullinated epi-
topes in early stages of RA (4-6). This is particularly
relevant since a definite diagnosis of RA is based on
clinical and radiographic criteria that usually are present
when some degree of irreversible structural damage to the
joints has already occurred. In this regard, it is noteworthy
that antibodies to citrullinated peptides have high positive
predictive value for identifying patients who will develop
definite RA among those with early undifferentiated polyar-
thritis (7).
However, once the diagnosis of RA is met there is still
one point to be defined. How erosive and incapacitating is
it going to be? The broad spectrum of severity of RA
ranges from a mild disease with low incapacity potential to
highly erosive and incapacitating forms (8,9). The knowl-
edge of the erosive potential of RA in a particular patient is
relevant to the therapeutic planning. Several elements
have been suggested as predictors of outcome, such as
early erosive disease, high erythrocyte sedimentation rate
and serum levels of C-reactive protein at the onset of the
disease, the presence of rheumatoid factor, and the pres-
ence of the shared DRB1 epitope (reviewed in Ref. 10).
Recent studies have demonstrated that antibodies to
citrullinated epitopes are quite efficient in predicting the
development of epiphysis erosions among patients with
early undifferentiated polyarthritis (7,11-13). This discrimi-
native ability may be related to the diagnostic property of
antibodies to citrullinated epitopes of differentiating pa-
tients with RA, an erosive disease, from patients with other
forms of polyarthritis with a benign course. However, it has
not been firmly established if this class of autoantibodies
can predict the erosive potential among patients with a
well-established diagnosis of RA. In the present study, we
evaluated the joint destruction rate in a series of patients
with well-defined RA along a 9-year interval according to
the presence of antibodies to citrullinated epitopes and
rheumatoid factor.
Patients and Methods
A series of 176 patients with RA according to the Ameri-
can College of Rheumatology classification criteria (14)
recruited by convenience was characterized in 1994 in a
tertiary university medical school (UNIFESP, São Paulo, SP,
Brazil) (15,16). Serum samples obtained in 1994 were stored
at –80°C. In 2002, extensive efforts led to the retrieval of 71
patients from this original series. After informed consent, all
71 patients underwent blood sampling, hand radiographs
(baseline foot radiographs were not available for several
patients), and the standard clinical protocol used in 1994.
Serum samples were kept at –80°C until use. Radiographs
obtained in 1994 and in 2002 were scored side by side for
Sharp’s index (17) by two experienced radiologists who
were unaware of the clinical and laboratory variables. The
difference in Sharp’s index obtained in 2002 and 1994 for
each patient was designated as Delta Sharp. The standard
evaluation protocol comprised clinical history, physical ex-
amination, duration of morning stiffness, number of swollen
joints, presence of extra-articular manifestations, and appli-
cation of the Health Assessment Questionnaire (HAQ) (18).
Physicians in charge of the clinical evaluation were blind to
the autoantibody status. The therapeutic regimen of the
cohort was rather homogeneous, comprising chloroquine
diphosphate and methotrexate plus non-steroidal anti-in-
flammatory drugs and/or low-dose oral prednisone (not ex-
ceeding 15 mg/day). No patient received immunosuppres-
sive or biological therapy.
Laboratory tests included erythrocyte sedimentation
rate and autoantibody determination. Rheumatoid factor
was determined by the standard latex agglutination tech-
nique (Dade Behring, Marburg, Germany). APF was deter-
mined by indirect immunofluorescence in buccal mucosa
cells from a single “positive” donor according to the stand-
ard technique (19). Anti-cyclic citrullinated peptide (CCP)
antibodies were determined by ELISA (Shield-axis, Eng-
land) according to manufacturer instructions, with a cut-off
of 20 AU/mL. Samples from 1994 and 2002 were pro-
cessed in parallel.
Contingency tables for qualitative variables were evalu-
ated by the chi-square test or Fisher’s exact test when
appropriate. Quantitative variables in two non-paired groups
were compared by the Mann-Whitney test. For dependent
groups, the Wilcoxon test was applied. Correlation be-
tween quantitative variables was estimated by the Pear-
son correlation coefficient. P values less than 0.05 were
considered significant.
Results
Of the 176 patients originally enrolled in the study in
1994 we were able to contact 71 patients (59 women and
12 men) in 2002. At the beginning of follow-up (1994) the
age of these 71 patients ranged from 21 to 77 years (mean
± SD: 46.7 ± 11.5 years). The series comprised patients
over a large span of disease duration (8.9 ± 6.7 years,
ranging from 0 to 25 years). Four patients had less than 2
years of disease, 25 had more than 2 and less than 5 years
of disease duration, 19 had more than 5 and less than 10
years of disease duration, and 23 patients had more than
10 years of disease duration.
Along the 9-year interval, the HAQ score increased
190 A.M. Nieto-Colonia et al.
Braz J Med Biol Res 41(3) 2008 www.bjournal.com.br
from 0.91 ± 0.74 (ranging from 0 to 2.38) at baseline in
1994 to 1.39 ± 0.72 (ranging from 0.13 to 2.88) in 2002.
The increase in HAQ score was statistically significant (P <
0.001). Accordingly, the number of swollen joints increased
from 4.6 ± 5.71 (median 3) in 1994 to 6.4 ± 4.1 (median 6)
in 2002 (P = 0.002). On the other hand, the duration of
morning stiffness decreased from 58 ± 72 min (median 20)
in 1994 to 31.8 ± 26.3 min (median 30) in 2002 (P = 0.03).
Rheumatoid factor above 80 IU/mL was observed in 48
patients (67.6%) in 1994 and in 46 patients (64.7%) in
2002. There was a significant increase in the serum con-
centration of rheumatoid factor in the 9-year interval (Table
1). APF was detected in 48 patients (67.6%) in 1994 and in
46 patients (64.8%) in 2002, with no significant variation in
titer (Table 1). Anti-CCP antibodies were present in 51
patients (71.8%) in 1994 and in 48 patients (67.6%) pa-
tients in 2002, with no significant variation in
serum concentration for the group as a whole
(Table 1). However, there was some variation in
titer for some patients although no relationship
to clinical features or therapeutic interventions
could be clearly identified (data not shown).
Along the 9-year interval there was a signifi-
cant increase in joint destruction as measured
by Sharp’s index (12 ± 18.2; Table 1). The rate
of joint destruction, as judged by Delta Sharp,
did not differ significantly according to the pres-
ence of rheumatoid factor, APF, and anti-CCP
antibodies (Table 2 and Figure 1). As can be
observed in Figure 1, the majority of patients
with Delta Sharp above 20 presented a positive
reaction for rheumatoid factor (75%), APF (69%),
and anti-CCP antibodies (81%). However, this
was not statistically different from the number of
patients with Delta Sharp under 20 presenting a
positive reaction for rheumatoid factor (65%),
APF (62%), and anti-CCP antibodies (69%).
Discussion
The present study analyzed the clinical, ra-
diographic, and immunologic features of a se-
ries of 71 RA patients along a 9-year interval. As
a group, there was progressive deterioration in
functional capacity and in joint structure. The
serum levels of APF and anti-CCP antibodies
tended to remain stable while serum levels of
rheumatoid factor increased along the 9-year
interval. There was no consistent association of
autoantibody status at baseline with rate of joint
destruction along the 9-year interval.
The outcome measure for evaluation of disease sever-
ity was the rate of joint destruction as measured by the
progression in Sharp index. Therefore, we calculated the
difference in Sharp index between the end and the begin-
ning of the study for each patient and tested the correlation
of this parameter with the autoantibody status at the begin-
ning of the study. No statistically significant correlation
between the baseline autoantibody status and the rate of
joint destruction was observed. When a subgroup of pa-
tients with a noticeably higher rate of joint destruction was
compared to the rest of the patients there was a slight over-
representation of positive reactions for the three autoanti-
bodies but with no statistical significance. It could be
argued that the ability to assess the rate of joint destruction
might be hampered in a sample of patients with long-
standing RA since a fraction of patients display more
Table 1. Characterization of 71 patients with rheumatoid arthritis in 1994 and
in 2002.
Parameter Year 1994 Year 2002
HAQ score 0.91 ± 0.74 1.39 ± 0.72*
Number of swollen joints 4.6 ± 5.71 6.4 ± 4.1*
Morning stiffness (min) 58 ± 72 31.8 ± 26.3*
Extra-articular manifestations 41 patients (58%) 44 patients (62%)
ESR (mm/1st hour) 31.2 ± 22.3 28.6 ± 21.5
Rheumatoid factor (IU/mL) 202.8 ± 357.6 416.6 ± 636.5*
APF (titer) Median = 1/10 Median = 1/10
(negative to 1/1280) (negative to 1/640)
Anti-CCP (AU/mL) 64.8 ± 48.8 58.9 ± 57.9
Sharp’s index 56.7 ± 62.1 92.4 ± 80.9*
Data are reported as means ± SD, unless otherwise indicated. HAQ = Health
Assessment Questionnaire; ESR = erythrocyte sedimentation rate: APF =
anti-perinuclear factor; anti-CCP = anti-cyclic citrullinated peptide antibodies.
*P < 0.05 compared to 1994 (Wilcoxon test).
Table 2. Difference in Sharp’s index (Delta Sharp) along a 9-year interval
according to the autoantibody status in 1994.
Autoantibody status in 1994
Autoantibody present Autoantibody absent
Rheumatoid factor N = 49 N = 22
13.79 ± 17.53 (9.56) 7.99 ± 19.29 (1.42)
APF N = 48 N = 23
12.43 ± 17.5 (7.80) 11.01 ± 19.83 (2.55)
Anti-CCP N = 50 N = 21
13.18 ± 17.59 (7.65) 8.89 ± 19.65 (2.23)
Data are reported as means ± SD and median in parentheses. APF = anti-
perinuclear factor; anti-CCP = anti-cyclic citrullinated peptide antibodies.
There were no statistical differences in antibody status (Wilcoxon test).
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fore, it is possible that at least part of the previously
published association between antibodies to citrullinated
epitopes and erosive features is actually due to the high
specificity of this system of autoantibodies for the diagno-
sis of RA. In fact, the present and previous studies with
patients with RA of longer duration (6,20) could not detect
a prognostic role for these autoantibodies.
The high rate of dropouts in the follow-up (starting with
176 and ending with 71 patients) and the poor clinical and
radiographic outcome of this series were probably related
to the specific characteristics of the population treated at
our service. The low income and social instability of this
particular population probably causes many of the patients
to move frequently to other regions of the city or of the
country. In fact, this same trend has been observed in
other outpatient clinics in several public hospitals in large
cities in Brazil. The low income also prevents access to
consistent therapy and is associated with low educational
level. Taken together, these factors are believed to ham-
per the efficiency of clinical treatment, a fact that may
partially explain the poor clinical and radiographic out-
come observed here.
It was remarkable that the serum levels of rheumatoid
factor increased along the 9-year interval while the serum
levels of APF and anti-CCP antibodies remained largely
unchanged. This observation probably reflects the uncon-
trolled clinical course of the disease in this series since it is
known that rheumatoid factor levels tend to decrease
when the disease moves towards remission (27).
Our data provide no evidence for rheumatoid factor
prominent joint destruction within the first 2 years of disease.
However, a substantial portion of patients exhibit a sus-
tained rate of joint destruction along several years (20,21). In
fact, the very purpose of the present study was to assess the
additional prognostic value of the autoantibodies in patients
with a well-established diagnosis of RA and for this purpose
the selected sample seemed to be the most appropriate. In
addition, an expressive progression in Delta Sharp for the
whole group of patients was observed along the 9-year
interval and that should be enough to reveal a putative
relevant prognostic effect for the autoantibodies.
There are several studies in the literature dealing with
the prognostic significance of rheumatoid factor and anti-
bodies to citrullinated epitopes. Some of them detected no
prognostic properties for antibodies to citrullinated epi-
topes (5,22,23). On the other hand, most studies did ob-
serve an association of erosive disease with antibodies to
citrullinated epitopes and/or rheumatoid factor (6,7,11-
13,24-26). Possible reasons for the discrepancy observed
in the literature include ethnic differences, distinct criteria
for patient selection, diverse methodological protocols,
and the presence of confounding variables such as thera-
peutic interventions. The apparent discrepancy between
the present findings and those of some previous studies is
probably due to patient selection. Most of the literature
studies included only patients with undifferentiated polyar-
thritis at baseline (8,12) or only patients with very early RA
(22-26). It is expected that part of these patients eventually
will present definite RA and part of them will turn out to
have some other benign form of chronic polyarthritis. There-
Figure 1. Distribution of the 71 patients with rheumatoid arthritis according to the Delta Sharp (Sharp’s index in 2002 minus Sharp’s
index in 1994) and the presence of rheumatoid factor (RF) (A), anti-perinuclear factor (APF) (B), and anti-cyclic citrullinated peptide
(CCP) antibodies (C). Gray triangles represent patients positive for the autoantibody and black squares represent patients negative
for the autoantibody. There was no significant difference in Delta Sharp according to the presence of the three autoantibodies
(Wilcoxon test).
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and antibodies to citrullinated epitopes having a role for
prognostic decisions on an individual basis in patients with
a well-established diagnosis of rheumatoid arthritis. This
conclusion may not be pertinent to patients with very early
rheumatoid arthritis or to patients first seen as a mild form
of the disease. At the clinical setting, the novel system of
autoantibodies to citrullinated peptides should be faced as
RA-specific immunologic markers, especially useful in as-
sisting the diagnosis and prognosis in the context of recent
onset polyarthritis.
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